Mitotic arrest deficiency 2 induces carcinogenesis in mucinous ovarian tumors

Nakano,Yusuke; Sumi,Toshiyuki; Morishita,Masanari; Fukuda,Takeshi; Nobeyama,Hiroyuki; Yoshida,Hiroyuki; Matsumoto,Yoshinari; Yasui,Tomoyo; Ishiko,Osamu

doi:10.3892/ol.2011.483

Mitotic arrest deficiency 2 induces carcinogenesis in mucinous ovarian tumors

Authors:
- Yusuke Nakano
- Toshiyuki Sumi
- Masanari Morishita
- Takeshi Fukuda
- Hiroyuki Nobeyama
- Hiroyuki Yoshida
- Yoshinari Matsumoto
- Tomoyo Yasui
- Osamu Ishiko
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Asahimachi, Abeno-ku, Osaka 545-8585, Japan
Published online on: November 15, 2011 https://doi.org/10.3892/ol.2011.483
Pages: 281-286

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitotic arrest deficiency 2 (MAD2) is a key component of the mitotic spindle checkpoint pathway. A compromised mitotic spindle checkpoint results in an abnormal number of chromosomes. This is referred to as chromosomal instability, and has been reported in most types of human cancer. The aim of this study was to examine the expression of MAD2 in mucinous ovarian tumors exhibiting varying degrees of malignancy. We reviewed 128 cases of mucinous ovarian tumors initially treated at Osaka City University Medical School Hospital, Japan. Tumor samples were obtained following surgery. The cases were divided into three groups: benign (group B; n=30), borderline malignant (group BM; n=55) and malignant (group M; n=43). MAD2 expression was examined in paraffin‑embedded sections using the avidin-biotin peroxidase complex method. Results showed MAD2 expression to be significantly greater in group M compared to groups B and BM (P<0.05). In addition, there was a moderate correlation between MAD2 expression and the degree of malignancy (r=0.51, P<0.05). However, when the samples in group M were classified according to a low or high expression of MAD2, no difference was observed in terms of overall survival. These findings suggest that the overexpression of MAD2 may be correlated to carcinogenesis in mucinous ovarian tumors.

View Figures

View References

1	Hardwick KG: Checkpoint signaling: Mad2 conformers and signal propagation. Curr Biol. 15:R122–R124. 2005. View Article : Google Scholar : PubMed/NCBI
2	Lopez-Girona A, Furnari B, Mondesert O and Russell P: Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature. 397:172–175. 1999. View Article : Google Scholar : PubMed/NCBI
3	Wang X, Jin DY, Ng RW, Feng H, Wong YC, Cheung AL and Tsao SW: Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res. 62:1662–1668. 2002.PubMed/NCBI
4	Li R and Murray A: Feedback control of mitosis in budding yeast. Cell. 66:519–531. 1991. View Article : Google Scholar : PubMed/NCBI
5	Orr-Weaver TL and Weinberg RA: A checkpoint on the road to cancer. Nature. 392:223–224. 1998. View Article : Google Scholar : PubMed/NCBI
6	Yoon DS, Wersto RP, Zhou W, Chrest FJ, Garret ES, Kwon TK and Gabrielson E: Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. Am J Pathol. 161:391–397. 2002. View Article : Google Scholar : PubMed/NCBI
7	Lengauer C, Kinzler KW and Vogelstein B: Genetic instability in colorectal cancer. Nature. 386:623–627. 1997. View Article : Google Scholar : PubMed/NCBI
8	Lengauer C, Kinzler KW and Vogelstein B: Genetic instability in human cancer. Nature. 396:643–649. 1998. View Article : Google Scholar
9	Sotillo R, Hernando E, Diaz-Rodriguez E, Teruya-Feldstein J, Cordon-Cardo C, Lowe SW and Benezra R: Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell. 11:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
10	To-Ho KW, Cheung HW, Ling MT, Wong YC and Wang X: MAD2ΔC induces aneuploidy and promotes anchorage-independent growth in human prostate epithelial cells. Oncogene. 27:347–357. 2008.
11	Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
12	Chen X, Cheung ST, So S, et al: Gene expression patterns in human liver cancers. Mol Biol Cell. 13:1929–1939. 2002. View Article : Google Scholar PubMed/NCBI
13	Garber ME, Troyanskaya OG, Schluens K, et al: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA. 98:13784–13789. 2001. View Article : Google Scholar : PubMed/NCBI
14	Li GQ and Zhang HF: Mad2 and p53 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol. 9:1972–1975. 2003.PubMed/NCBI
15	Li GQ and Zhang HF: Mad2 and p27 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol. 10:3218–3220. 2004.PubMed/NCBI
16	Zhang SH, Xu AM, Chen XF, Li DH, Sun MP and Wang YJ: Clinicopathologic significance of mitotic arrest defective protein2 overexpression in hepatocellular carcinoma. Hum Pathol. 39:1827–1834. 2008. View Article : Google Scholar : PubMed/NCBI
17	Wang L, Yin F, Du Y, Du W, Chen B, Zhang Y, Wu K, Ding J, Liu J and Fan D: MAD2 as a key component of mitotic checkpoint: A probable prognostic factor for gastric cancer. Am J Clin Pathol. 131:793–801. 2009. View Article : Google Scholar : PubMed/NCBI
18	Tanaka K, Nishioka J, Kato K, Nakamura A, Mouri T, Miki C, Kusunoki M and Nobori T: Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancer. Jpn J Cancer Res. 92:952–958. 2001. View Article : Google Scholar
19	Yu L, Guo WC, Zhao SH, Tang J and Chen JL: Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma. APMS. 118:222–9. 2010. View Article : Google Scholar : PubMed/NCBI
20	Wu CW, Chi CW and Huang TS: Elevated level of spindle checkprotein MAD2 correlates with cellular mitotic arrest, but not with aneuploidy and clinicopathological characteristics in gastric cancer. World J gastroenterol. 10:3240–3244. 2004.PubMed/NCBI
21	Sotillo R, Schvartzman JM, Socci ND and Beneztra R: Mad2- induced chromosome instability leads to lung tumor relapse after oncogene withdrawal. Nature. 464:436–40. 2010. View Article : Google Scholar : PubMed/NCBI
22	Scully RE, Young RH and Clement PB: Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament. Atlas of tumor pathology. (3rd series). fascicle 23. Armed Forces Institute of pathology; Washington DC: 1998, PubMed/NCBI
23	Hart WR: Borderline epithelial tumors of the ovary. Mod Pathol. 18:S33–50. 2005. View Article : Google Scholar : PubMed/NCBI
24	Lee KR and Scully RE: Mucinous tumors of the ovary: a clinicopathologic study 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with ‘pseudomyxoma peritonei’. Am J Surg Pathol. 28:1311–1318. 2002.PubMed/NCBI
25	Winter WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F and McGuire WP: Prognostic factors for stageIII epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 25:3621–3627. 2007. View Article : Google Scholar : PubMed/NCBI
26	Puls LE, powell DE, DePriest PD, Gallion HH, Hunter JE, Kryscio RJ and van Nagell JR: Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol. 47:53–57. 1992. View Article : Google Scholar : PubMed/NCBI
27	Garrett AP, Lee KR, Colitti CR, Muto MG, Berkowitz RS and Mok SC: K-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol. 20:244–251. 2001. View Article : Google Scholar : PubMed/NCBI
28	Wamunyokoli FW, Bonome T, Lee JY, Feltmate CM, Welch WR, Radonovich M, Pise-Masison C, Brady J, Hao K, Berkowitz RS, Mok S and Birrer MJ: Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res. 12:690–700. 2006. View Article : Google Scholar : PubMed/NCBI
29	Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI